Related Experiment Video

Updated: Jan 29, 2026

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.1K

New and Future Parenteral Therapies for the Management of Lipid Disorders

Roberto Garcia1, Jaime Burkle2

  • 1Unidad Médica de Alta Especialidad, Hospital de Cardiologia No. 34 Instituto Mexicano del Seguro Social, Monterrey, NL, México.

Archives of Medical Research
|February 12, 2019
PubMed

Insights

Cardiovascular disease (CVD) remains a leading cause of death globally. New parenteral therapies offer future hope for managing lipid disorders, especially for high-risk patients with dyslipidemia who don't meet LDL-C goals with current treatments.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is the primary global cause of mortality, accounting for 31% of all deaths in 2016.
  • Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease.
  • Current treatments fail to achieve LDL-C goals in a substantial proportion of high-risk CVD patients, including 80% of those with familial hypercholesterolemia (FH) on maximal statin therapy.

Purpose of the Study:

  • To review current challenges in lipid disorder management.
  • To discuss novel and emerging parenteral therapies for dyslipidemia.
  • To highlight potential advancements in achieving LDL-C goals for high-risk cardiovascular patients.

Main Methods:

  • Literature review of existing cardiovascular disease statistics and risk factors.
  • Analysis of current therapeutic outcomes for dyslipidemia.
  • Exploration of emerging parenteral treatment strategies for lipid management.

Main Results:

  • Dyslipidemia significantly contributes to cardiovascular mortality, including myocardial infarction and stroke.
  • A majority of high-risk CVD patients and a large percentage of FH patients do not reach target LDL-C levels with existing therapies.
  • Parenteral therapies represent a promising avenue for improved lipid management.

Conclusions:

  • Effective management of dyslipidemia is critical to reduce the global burden of cardiovascular disease.
  • Novel parenteral therapies are under development to address unmet needs in lipid management.
  • Future therapeutic strategies aim to improve LDL-C goal attainment in high-risk patient populations.

Keywords:
AlipogeneAntisense oligonucleotidesCardiovascular diseaseDyslipidemiaInclinsiranLDLLipid disorders therapyPCSK9sIRNA

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

802
The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders10:08

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders

Published on: August 25, 2022

3.3K

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
725
What are Lipids?01:38

What are Lipids?

Overview
220.0K
Routes of Drug Administration: Parenteral01:25

Routes of Drug Administration: Parenteral

The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
2.9K
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.7K
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
99.2K
Structure of Lipids03:38

Structure of Lipids

Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic...
98.7K